Galectin Therapeutics Inc. (GALT)
$3.64-1.36%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $240M
- Beta
- 0.38
- P/E (TTM)
- -8.52
- Short % float
- 19.62%
- Days to cover
- 33.7
- SI change
- -1.4%
- 1W
- +0.55%
- 1M
- -2.41%
- vs SPY 1W
- +0.69%
- vs SPY 1M
- -4.92%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 3
- GROWTH
- 35
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC12.9%
REV YoY-
ROE21.5%
EPS YoY-
ROA-187.8%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-8.52
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B-1.75
P/FCF-
EV/EBITDA-26.48
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.10
ND/EBITDA-
BETA0.38
Company news
FAQ
- What is LOPJLB’s current signal on GALT?
- LOPJLB’s latest quantitative signal on Galectin Therapeutics Inc. (GALT) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is GALT in?
- Galectin Therapeutics Inc. (GALT) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Galectin Therapeutics Inc. (GALT) do?
- Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergo…